During the year 2022-23, the I131-MIBG program for high-risk neuroblastoma made significant progress with record-high enrolment of patients in the OPTIMUM Phase II clinical trial. In 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback